Real‐World Outcomes of Thromboprophylaxis With Apixaban in Patients With Newly Diagnosed Multiple Myeloma, the MyelMeXa Study
K Alexandra Sanchez, Gabriela Cesarman‐Maus, Michelle Flores‐Cruz, Beatriz Cabello, Ramiro Espinoza, Omar Eduardo Fernandez‐Vargas · 2026
Read Real‐World Outcomes of Thromboprophylaxis With Apixaban in Patients With Newly Diagnosed Multiple Myeloma, the MyelMeXa Study by K Alexandra Sanchez, Gabriela Cesarman‐Maus, Michelle Flores‐Cruz, Beatriz Cabello, Ramiro Espinoza, Omar Eduardo Fernandez‐Vargas (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13244662.txt.
Description
K. Alexandra Sanchez and colleagues followed newly diagnosed myeloma patients given apixaban to prevent blood clots. Their prospective study appeared in EJHaem in 2026. Myeloma and its treatments carry one of the highest clot risks in cancer care, and plain aspirin often underprotects. Eighty-seven consecutive patients at one center took the oral factor Xa blocker as their main preventive and were watched for clots and bleeding over a median of eleven months.
The record was strikingly clean. No major bleeding occurred, and no deep vein thrombosis or lung embolism appeared during follow-up. Two patients developed symptomatic clots in surface veins, the only thrombotic events recorded. The authors judge the drug safe in this role and its event rates very low. They stop short of declaring victory, calling for controlled comparison before guidelines change. For a population used to injectable prevention, an effective pill would simplify life considerably.
Catalog record
| CREATOR | K Alexandra Sanchez, Gabriela Cesarman‐Maus, Michelle Flores‐Cruz, Beatriz Cabello, Ramiro Espinoza, Omar Eduardo Fernandez‐Vargas |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 15 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |